Milestone Scientific, Inc. (NYSE MKT: MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Since 1995, the company’s commitment to advancing the science of computer-controlled drug delivery technologies has helped it earn global distinction as an industry leader in the fields of medicine and dentistry. Milestone’s patented CompuFlo® system and DPS Dynamic Pressure Sensing® technology are revolutionary tools that enable practitioners to accomplish a collection of tasks that exceed the capabilities of the 150 year-old manual syringe.
The CompuFlo® system provides a safer, painless delivery alternative for all types of subcutaneous injections in the medical practice. Utilizing Milestone’s proprietary pressure sensing technology, the system offers safe, effective feedback to assist healthcare providers in identifying a specific anatomic location. In addition to more accurate injections, the platform is capable of documenting injection events to provide more reliable recordkeeping for both patients and healthcare providers.
In recent months, Milestone, through its Epidural & IA subsidiary, has turned its attention towards a clinical trial to verify the placement of the epidural needle tip in the lumbar epidural space. Since receiving FDA approval in March, the company has opened enrollment for clinical testing, aiming to enroll up to 400 patients in the trial at four sites throughout the United States.
“A major focus of the Company in 2015 is commercializing the first medical applications of our technology platform, including those licensed by our Epidural & IA Subsidiary,” stated Leonard Osser, Chief Executive Officer of Milestone. “Our Epidural & IA Subsidiary has been in negotiations with distributors in a number of countries… [and] recently signed its first distribution agreement with TRIMED SP.z.o.o., one of the largest distributors of diagnostic equipment in Poland.”
In the first quarter of 2015, Milestone made took major steps towards realizing sustainable growth by signing a letter of intent with MILA International for marketing, distribution and commercialization of an anesthetic delivery instrument for maxillary nerve block procedures in horses. Through this agreement, the company will gain access to the $24 billion global animal health industry, providing an additional platform for continued expansion.
“Our strategy is to collaborate on the development, commercialization and distribution of an anesthetic delivery instrument… [for which] MILA will be responsible for marketing and distribution and Milestone will manufacture product,” continued Osser.
For prospective investors, the company’s continued dedication to innovation and an increasingly broad collection of target markets provide the opportunity to realize sustainable returns in the future.
For more information, visit www.milesci.com
